Description:1.IntendedUse TheGenWayEBVEAIgGAntibodyELISATestKithasbeendesignedforthethedetectionand thequantitativedeterminationofspecificIgGantibodiesagainstEBVEAinserumandplasma. FurtherapplicationsinotherbodyfluidsarepossIBLeandcanberequestedfromtheTechnical ServiceofGenWay. Thisassayisintendedforresearchuseonly. 2.GeneralInformation In1961aninfectiousdiseasewasidentifiedinUganda,whichwascorrelatedwiththeappearance ofadefinedtypeoftumorwithchildren.Theillness,whichisfoundpredominantlyinAfricaand Papua-NewGuinea,wasnamedBurkittlymphomafromitsdiscoverer.In1964,Epstein,Barrand Achongcharacterizedbyelectronmicroscopyasthecausingagentahithertounknownvirus,which belongstothefamilyofherpesviruses.TheEpsteinBarrvirusismaderesponsibleforavarietyof diseaseslikeinfectiousmononucleosis,Burkittlymphoma,aswellasnasopharyngealcarcinoma.In addition,aroleofthevirusisdiscussedinconnectionwithHodgkin´sdisease.Especiallywith teenagersthereappearsaglandularfeversyndrome,whichiscalled&BDquo;kissingdisease“.Diseases whicharecausedbytheEpsteinBarrvirusarefoundmainlyinpersonswithreducedimmunity.For example,thevirusisassociatedwithalymphoproliferativediseasewhichoccursafter transplantation.Theimmunesystemofsuchindividualsisusuallyimpairedbydrugtherapy.Also inimmune-deficientAIDSindividuals,thereappearsfrequentlyastatewherecellsattherimofthe tongueareinfected(oralhairyleukoplakia).InfectedpersonskeeptheEpstein-Barrvirusforeverin theirbody,theyarehowevermostlynotill.Inthedevelopingcountriespracticallyallthepeopleare infected,inthewesternworldtheincidenceisbetween80%and90%.Thetransmittanceoccurs alreadyduringchildhood,perhapsbytransferfromthemother,mainlyviathesaliva.Duringthe activephaseoftheviralcycle,theEpstein-Barrvirusproducesabout100differentantigens,inthe inactivephasearound10.ThelattercomprisesamongotherstheEBVnuclearantigenEBNA-1, whichiscloselycorrelatedwithapastinfectionandanimmunity.Theearlyantigen(EA)aswellas theviruscapsidantigen(VCA)fromtheactivephasearealsousedasdiagnosticMarkers.Inafresh infection,IgMantibodiesagainstVCAandEAaredeterminedbyimmunofluorescenceorELISA. LaterVCAIgGandafterwardsEBNA-1IgGantibodiesappear.Thesimultaneousactivationof VCAIgMandEBNA-1IgGindicatescorrespondinglyareactivationofalatentEBVinfection. 3.PrincipleoftheTest TheGenWayEBVEAIgGantibodytestkitisbasedontheprincipleoftheenzymeimmunoassay (EIA).EBVEAantigenisboundonthesurfaceofthemicrotiterstrips.Dilutedsampleserumor ready-to-usestandardsarePipettedintothewellsofthemicrotiterplate.AbindingbetweentheIgG antibodiesoftheserumandtheimmobilizedEBVearlyantigentakesplace.Afteraonehour incubationatroomtemperature,theplateisrinsedwithdilutedwashsolution,inordertoremove unboundmaterial.Thenready-to-useanti-human-IgGperoxidaseconjugateisaddedandincubated for30minutes.Afterafurtherwashingstep,thesubstrate(TMB)solutionispipettedandincubated for20minutes,inducingthedevelopmentofabluedyeinthewells.Thecolordevelopmentis terminatedbytheadditionofastopsolution,whichchangesthecolorfrombluetoyellow.The resultingdyeismeasuredspectrophotometricallyatthewavelengthof450nm.Theconcentration oftheIgGantibodiesisdirectlyproportionaltotheintensityofthecolor. AdditionalInformation:NameEBVEarlyAntigenIgGELISARelatedProductNamesEBVEarlyAntigenIgGELISAApplicationsEnzymeimmunoassaybasedonmicrotiterplateforthedetectionandquantitativedeterminationofhumanIgGantibodiesagainstEBVEarlyAntigeninserumandplasmaIntendedUseResearchUseOnly